2024
Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes
Zhang T, Niu N, Taddei T, Jain D, Zhang X. Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal Of Clinical Pathology 2024, aqae136. PMID: 39418121, DOI: 10.1093/ajcp/aqae136.Peer-Reviewed Original ResearchSH-HCCSteatohepatitic hepatocellular carcinomaHepatocellular carcinomaLiver diseaseHepatitis C virus infectionC virus infectionStage of fibrosisPresence of steatohepatitisOverall survivalHistological subtypesPrognostic factorsHCC subtypesBackground liverHCC casesClinicopathological featuresConventional HCCHistopathological patternsHyaline globulesTumor cellsMallory-Denk bodiesGlycogenated nucleiSteatotic liver diseaseHCCSurvival analysisSteatohepatitisScreening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosis
2022
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolizationImpact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances In Gastroenterology 2022, 15: 17562848221100106. PMID: 36199289, PMCID: PMC9527996, DOI: 10.1177/17562848221100106.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseImpact of NAFLDBody mass indexOverall survivalHepatocellular carcinomaLiver diseasePresence of NAFLDMultivariable Cox proportional hazardsMedian body mass indexAdvanced-stage hepatocellular carcinomaGrade 2 hypertensionLower starting doseInternational cohort studySimilar clinical benefitsFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseAdverse eventsCohort studyPrognostic factorsClinical outcomesMass indexClinical benefit
2021
The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma
Sellers CM, Uhlig J, Ludwig JM, Pollak JS, Taddei TH, Stein SM, Lim JK, Kim HS. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine 2021, 10: 5395-5404. PMID: 34318618, PMCID: PMC8366096, DOI: 10.1002/cam4.3573.Peer-Reviewed Original ResearchConceptsChronic viral hepatitisViral hepatitisHepatocellular carcinomaMultivariable analysisMedian OSNLR groupHepatitis CKaplan-Meier overall survival curvesCox hazard proportional modelHigher median OSLow baseline NLROverall survival curvesTertiary care institutionBaseline NLRDecreased OSNonviral hepatitisHigh NLRInflammatory biomarkersLow NLRMultivariable adjustmentOverall survivalLymphocyte ratioPrognostic valueRetrospective studyPrognostic relevanceImpact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam V, Bettinger D, Thimme R, Taddei T, Kaplan D, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study. Journal Of Clinical Oncology 2021, 39: 289-289. DOI: 10.1200/jco.2021.39.3_suppl.289.Peer-Reviewed Original ResearchImpact of NAFLDOverall survivalHepatocellular carcinomaLiver diseaseNon-alcoholic fatty liver diseaseMultivariable Cox proportional hazardsAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseMedian BMIPrognostic factorsSpecialist centresHCC patientsNAFLDTreatment responseInternational cohortPatientsSorafenibDemographic dataSurvival
2020
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal Of Cancer 2020, 124: 407-413. PMID: 33071284, PMCID: PMC7852559, DOI: 10.1038/s41416-020-01116-9.Peer-Reviewed Original ResearchConceptsOverall survivalHepatocellular carcinomaCohort studySorafenib-related toxicityInternational cohort studyMedian overall survivalMulticentre cohort studyLow-dose therapyCommon prognostic factorsSimilar overall incidenceDoses of sorafenibImpact of ageConclusionsClinical outcomesSorafenib 800Sorafenib dosingElderly patientsOlder patientsPrognostic factorsOverall incidenceClinical efficacyLiver functionLarge tumorsMultivariable modelGrade 2PatientsAn international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.
Sharma R, Hajiev S, Aval L, Bettinger D, Arizumi T, Pirisi M, Rimassa L, Personeni N, Pressiani T, Giordano L, Kudo M, Thimme R, Park J, Taddei T, Kaplan D, Ramaswami R, Pinato D, Allara E. An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib. Journal Of Clinical Oncology 2020, 38: 12049-12049. DOI: 10.1200/jco.2020.38.15_suppl.12049.Peer-Reviewed Original ResearchOverall survivalStarting doseHepatocellular carcinomaAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityMedian overall survivalMulticentre cohort studyPortal vein thrombosisTerms of OSLow-dose therapyDose of sorafenibRates of toxicitySorafenib dosingSorafenib toxicityChild-PughDose therapyCohort studyElderly patientsOlder patientsVein thrombosisClinical efficacySimilar incidenceSpecialist centresLarge tumors
2019
The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance
Sellers CM, Uhlig J, Ludwig JM, Taddei T, Stein SM, Lim JK, Kim HS. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. Cancer Medicine 2019, 8: 5948-5958. PMID: 31436905, PMCID: PMC6792508, DOI: 10.1002/cam4.2251.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaPrivate insuranceInsurance statusMedicaid patientsCox proportional hazards modelAdvanced liver diseaseChild-Pugh BHigh MELD scoreAmerican Joint CommitteeKaplan-Meier curvesProportional hazards modelInsurance groupsMELD scoreOverall survivalIndependent predictorsLiver diseaseMultivariable analysisTumor burdenCancer RegistryTumor sizePotential confoundersSurvival differencesCancer stageUnivariate analysisC diseaseMacrotrabecular Hepatocellular Carcinoma
Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma. The American Journal Of Surgical Pathology 2019, 43: 943-948. PMID: 31135484, DOI: 10.1097/pas.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlpha-FetoproteinsCarcinoma, HepatocellularDisease ProgressionFemaleHepatectomyHepatitis BHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingProgression-Free SurvivalRetrospective StudiesRisk FactorsTime FactorsTumor BurdenConceptsHepatocellular carcinomaHCC subtypesHigh alpha-fetoprotein levelsWorse recurrence-free survivalDistinct HCC subtypeHepatitis C infectionRecurrence-free survivalAlpha-fetoprotein levelsAnaplastic tumor cellsHigh histologic gradePoor overall survivalConventional hepatocellular carcinomaHigh recurrence rateHigher AJCC stageDetailed pathologic evaluationMacrotrabecular patternC infectionPrimary resectionHepatitis BOverall survivalPathologic evaluationAJCC stageClinicopathologic featuresHistologic subtypeRecurrence rate
2018
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching
Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal Of Vascular And Interventional Radiology 2018, 29: 540-549.e4. PMID: 29477619, PMCID: PMC6104514, DOI: 10.1016/j.jvir.2017.11.033.Peer-Reviewed Original ResearchConceptsUnresectable hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaMacrovascular invasionPropensity matchingOverall survivalEnd-stage liver disease (MELD) scoreBarcelona Clinic Liver Cancer stageVeterans Health Administration hospitalsInitiation of sorafenibSignificant hepatic dysfunctionLiver Disease scoreRetrospective cohort studyAdjuvant transarterial chemoembolizationLiver Cancer stageMulti-institutional studySorafenib initiationHepatic dysfunctionCohort studyMost patientsSystemic therapyPrimary outcomeUnadjusted analysesMultimodal therapySubgroup analysisThe effect of socioeconomic factors on the outcome of hepatocellular carcinoma.
Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.Peer-Reviewed Original ResearchMedian overall survivalCancer-directed treatmentOverall survivalHepatocellular carcinomaPrivate insurancePrimary insuranceInner-city tertiary care hospitalDecreased median overall survivalCox proportional hazard modelingMultivariate Cox proportional analysisCox proportional analysisTertiary care hospitalOS of patientsKaplan-Meier curvesProportional hazard modelingSocioeconomic factorsMedian OSSurvival benefitCare hospitalConsecutive patientsAJCC stageCancer RegistryMean ageTreatment courseSurvival advantageSorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma
Kaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalBarcelona Clinic Liver Cancer (BCLC) systemManagement of HCCVeterans Health Administration hospitalsRetrospective cohort studyFirst-line therapySimilar survival outcomesChild-TurcottePugh scoreComorbidity indexChart abstractionCohort studySurvival benefitSystemic therapyBCLC stagePrimary outcomePrescriber typeSurvival outcomesAdministration HospitalMultivariable modelProvider specialtyCancer stagingHCC diagnosis
2017
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study
Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. Journal Of Clinical Oncology 2017, 35: jco.2017.73.824. PMID: 28872925, PMCID: PMC5662845, DOI: 10.1200/jco.2017.73.8245.Peer-Reviewed Original ResearchConceptsSorafenib patientsHazard ratioOverall survivalHepatocellular carcinomaPotential confoundersNoninferiority marginEnd-stage liver disease-sodium (MELD-Na) scoreVeterans Health Administration hospitalsHigher Child-TurcottePotential treatment biasReduced pill burdenComorbidity Index scorePrimary end pointFirst-line therapyGastrointestinal adverse effectsDose of sorafenibSignificant OS differenceAdvanced hepatocellular carcinomaLower overall survivalMultivariate logistic regressionMulti-institutional studyChild-TurcotteOS relativePugh scorePurpose SorafenibAssociation of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality
Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE, Group V. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017, 152: 1954-1964. PMID: 28283421, PMCID: PMC5664153, DOI: 10.1053/j.gastro.2017.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChi-Square DistributionDelivery of Health Care, IntegratedFemaleGastroenterologistsHumansKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioOncologistsPatient Care TeamPractice Patterns, Physicians'Proportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSpecializationSurgeonsTime FactorsTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsRetrospective cohort studyMultidisciplinary tumor boardHealth system factorsHepatocellular carcinomaHCC therapyCohort studyOverall survivalTumor boardTime-varying Cox proportional hazards modelsCox proportional hazards modelActive hepatocellular carcinomaOutcomes of patientsProportional hazards modelHepatocellular carcinoma treatmentVeterans Administration HospitalSystem factorsLiver transplantationActive therapyLiver resectionTransarterial therapiesMedical oncologistsMultidisciplinary careSubspecialist carePatient survivalAblative therapyUp-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.
Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.Peer-Reviewed Original ResearchDuration of exposureBCLC BICD9 codesBarcelona Clinic Liver Cancer stageInitiation of sorafenibMedian overall survivalLiver Cancer stageLonger exposure durationECOG PSExposure durationUp-titrationChild-TurcotteMELD scoreSorafenib therapyFirst doseOverall survivalPharmacy recordsMedian agePrescription fillsLiver diseaseTumor numberC-HCCEquivalent survivalHCC patientsCancer stage
2011
Systemic Therapy in Hepatocellular Carcinoma
Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic Therapy in Hepatocellular Carcinoma. Clinics In Liver Disease 2011, 15: 423-441. PMID: 21689622, PMCID: PMC3758582, DOI: 10.1016/j.cld.2011.03.002.Books
2004
Impact of body mass index on graft failure and overall survival following liver transplant*
Rustgi VK, Marino G, Rustgi S, Halpern MT, Johnson LB, Tolleris C, Taddei TH. Impact of body mass index on graft failure and overall survival following liver transplant*. Clinical Transplantation 2004, 18: 634-637. PMID: 15516235, DOI: 10.1111/j.1399-0012.2004.00141.x.Peer-Reviewed Original ResearchConceptsElevated body mass indexBody mass indexLower body mass indexLikelihood of deathMass indexLiver transplantLiver transplantationGraft failureImpact of BMIHigher body mass indexGraft failure rateNumber of comorbiditiesOrgan Sharing databaseOverall survival rateProportional hazards regressionRisk of deathOverall survivalSharing databaseHazards regressionUnited NetworkRisk factorsBMI valuesPatientsSurvival rateDecreased likelihood